Three years after Sanofi signed on to back Cambridge, MA-based Warp Drive Bio, taking an option to buy, the pharma giant has stepped back up to retool the terms, opting for a 5-year collaboration potentially worth $750 million while leaving the biotech free to pursue its own independent future.
Cambridge, MA-based Warp Drive Bio is launching a new cancer drug platform which the biotech claims will open up new, previously undruggable targets to developers.
Warp Drive Bio, at work on high-tech therapeutics derived from nature, appointed biopharma veteran Laurence Reid as its new CEO, with ex-chief and Harvard luminary Greg Verdine pivoting to president and chief scientific officer.
After co-founding Warp Drive, which launched last year to discover natural product drugs, Professor Gregory Verdine has taken over the chief executive role from Third Rock Ventures partner Alexis Borisy.
The world's biggest biotechs are piling up data by the petabyte, amassing numbers for gene expression, biomarker reliability, patient outcomes and pretty much every other measurable vector in drug development. Of course, to date, no disease has ever been treated by a spreadsheet, so how do we take Big Data from the server closet to the doctor's office?
Biotech startup Warp Drive Bio has scored $125 million in financing from a syndicate that features the French drug giant Sanofi ($SNY) along with founding backer Third Rock Ventures and the VC firm